Get the Stockscreener App
0.287
3.91%
0.0108
Bioline Rx Ltd Adr Stock (BLRX) Latest News
BioLineRx stock target cut, retains buy on Q3 financial results - Investing.com
BioLineRx Reports Strategic Moves in Q3 2024 - TipRanks
BioLineRx earnings beat by $0.04, revenue topped estimates By Investing.com - Investing.com South Africa
BioLineRx earnings beat by $0.04, revenue topped estimates - Investing.com India
Earnings call: BioLineRx announces Q3 results and strategic shifts - Investing.com
BioLineRx Secures Key Deals to Boost Shareholder Value - TipRanks
IO Biotech Inc (NASDAQ: IOBT) Is A Buzzing Hot Stock - Stocks Register
BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell - Yahoo Finance
BioLineRx stock hits 52-week low at $0.38 amid market challenges - Investing.com
BiolineRx Ltd. Announces New Direct Offering of Shares - TipRanks
SEC Form 424B5 filed by BioLineRx Ltd. - Quantisnow
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 - Benzinga
BioLineRx Granted Extension to Meet Nasdaq Requirements - TipRanks
BioLineRx’s Motixafortide Shows Promise in Sickle Cell Trials - TipRanks
BioLineRx stock hits 52-week low at $0.39 amid market challenges - Investing.com India
BioLineRx Secures Extended U.S. Patent for Motixafortide - TipRanks
BioLineRx secures US patent for cancer drug motixafortide - Investing.com
BioLineRx secures US patent for cancer drug motixafortide By Investing.com - Investing.com UK
BioLineRx stock hits 52-week low at $0.43 amid market challenges - Investing.com
Riding the Waves: A Guide to Investing in BLRX Stock - The InvestChronicle
Market Insight: Bioline Rx Ltd ADR (BLRX)’s Notable Drop, Closing at 0.46 - The Dwinnex
BioLineRx stock hits 52-week low at $0.5 amid market challenges - Investing.com
BioLineRx Ltd. Shareholders Approve Key Resolutions - TipRanks
Bioline Rx Ltd ADR (BLRX) Stock: A Year of Market Fluctuations - The InvestChronicle
Stock Market Recap: Bioline Rx Ltd ADR (BLRX) Concludes at 0.54, a -13.53 Surge/Decline - The Dwinnex
A new trading data show Bioline Rx Ltd ADR (BLRX) is showing positive returns. - SETE News
Metric Analysis: Bioline Rx Ltd ADR (BLRX)’s Key Ratios in the Limelight - The Dwinnex
BLRX overperforms with a 0.95 increase in share price - US Post News
Australia Single Molecule, Real-Time (SMRT) Sequencing Market Size & Outlook, 2030 - Grand View Research
BioLineRx Schedules Annual Shareholders Meeting - TipRanks
Financial Analysis: Bioline Rx Ltd ADR (BLRX)’s Ratios Unveil Key Insights - The Dwinnex
BLRX Stock: Exploring Bioline Rx Ltd ADR’s Growth - The InvestChronicle
Earnings call: BioLineRx beats Q2 goals with strong APHEXDA demand - Investing.com
BioLineRx’s Strong Quarter with APHEXDA Growth - TipRanks
Options Volatility and Implied Earnings Moves Today, August 15, 2024 - TipRanks
Bioline Rx Ltd ADR’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
Ratio Revelations: Bioline Rx Ltd ADR (BLRX)’s Financial Metrics in the Spotlight - The Dwinnex
There is no doubt that Bioline Rx Ltd ADR (BLRX) ticks all the boxes. - SETE News
Bioline Rx Ltd ADR (BLRX) stock analysis: A simple moving average approach - US Post News
BLRX’s Stock Journey: What Investors Need to Know About Bioline Rx Ltd ADR’s Performance - The InvestChronicle
Financial Analysis: Bioline Rx Ltd ADR (BLRX)'s Ratios Unveil Key Insights – DWinneX - The Dwinnex
Bioline Rx Ltd ADR Inc. (BLRX) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
BLRXBioLineRx Reports Second Quarter 2011 Financial Results - br.ADVFN.com
What Can Bioline Rx Ltd ADR (NASDAQ: BLRX) Expect In 2024? – Stocks Register - Stocks Register
Bioline Rx Ltd ADR (BLRX) stock: A year of ups and downs – US Post News - US Post News
Bioline Rx Ltd ADR (BLRX)'s Market Momentum: Closing Strong at 0.69, Down -4.03 – DWinneX - The Dwinnex
BioLineRx Trials New Sickle Cell Gene Therapy - TipRanks
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applicatio - Investing.com India
Understanding the Risks of Investing in Bioline Rx Ltd ADR (BLRX) – Knox Daily - Knox Daily
Earnings call: BioLineRx Q1 2024 results show steady progress - Investing.com India
Earnings call: BioLineRx Q1 2024 results show steady progress By Investing.com - Investing.com
BioLineRx Q1 Success with APHEXDA® Growth - TipRanks
Bioline Rx Ltd ADR (BLRX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Are Smart Investors Making the Right Decision? Bioline Rx Ltd ADR (BLRX) – Sete News - SETE News
BioLineRx to present new data from CheMo4METPANC Phase 2 at ASCOTipRanks.com - TipRanks
BioLineRx reports positive pancreatic cancer trial results By Investing.com - Investing.com
BioLineRx Showcases Promising Cancer Drug Trial Results - TipRanks
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):